# Jade Biosciences, Inc. (JBIO)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/jade-biosciences-inc/ JSON: https://steadybase.io/company/jade-biosciences-inc.json Checked Nov 21, 2026. Latest filing read: Nov 13, 2026.

## Company

- Legal name: Jade Biosciences, Inc.
- Ticker: JBIO (Nasdaq)
- SEC CIK: 0001798749
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Waltham, MA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: jadebiosciences.com
- Investor relations: https://jadebiosciences.com/investors/
- LinkedIn: https://www.linkedin.com/company/jade-biosciences
- Next earnings date: Feb 11, 2027

## Key facts

- Operating income: -$113.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/0001193125-26-096550-index.html
- Net income: -$127.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/0001193125-26-096550-index.html
- SG&A: $20.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/0001193125-26-096550-index.html
- Employees: 55 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm
- Shares outstanding: 69,189,448 as of Nov 6, 2026 (10-Q filed Nov 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526459293/0001193125-26-459293-index.html
- Auditor: Pricewaterhousecoopers LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm

## Business

We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm

## Officers and directors

- Tom Frohlich, Chief Executive Officer & Director. Source: 10-K filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm
- Bradford D. Dahms, Chief Financial Officer. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1798749/000119312526052056/0001193125-26-052056-index.htm
- Erin Lavelle, Director. Source: 10-K filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm
- Tomas Kiselak, Director. Source: 10-K filed Mar 6, 2026, https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm

## Recent 8-K events

- Nov 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312d8k.htm
- Sep 30, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/d936098d8k.htm
- Aug 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm
- Jul 1, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/d145208d8k.htm
- Jun 26, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526283906/d127137d8k.htm
- Jun 11, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526267640/d161530d8k.htm
- Jun 4, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526257733/d103726d8k.htm
- Jun 1, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/d108669d8k.htm
- Apr 22, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/d90643d8k.htm

## What management said

- "The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones" Tom Frohlich, Chief Executive Officer of Jade (8-K filed Nov 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312dex991.htm
- "This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety profile, strengthening our conviction to rapidly advance the compound to deliver a potentially best-in-class profile in IgA nephropathy" Tom Frohlich, Chief Executive Officer of Jade Biosciences (8-K filed Aug 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm

## Latest filings

- 8-K filed Sep 30, 2026: https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/d936098d8k.htm
- 10-K filed Mar 6, 2026: https://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm
- 10-Q filed Aug 10, 2026: https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/ck0001798749-20260630.htm
- DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1798749/000119312526187059/d52810ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

